Astellas is committed to providing timely and accurate information about our business, science and products. This section offers global resources for investors, journalists and media professionals. News and resources from our local affiliates can be viewed in the Local news section. If you are not an investor or journalist, click here.
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Tokyo, March 1, 2018 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “Astellas” ) today announced that 40 mg XTANDI Tablets and 80 mg XTANDI Tablets received...
Tokyo, February 16, 2018 - Astellas Pharma Inc. (President and CEO: Yoshihiko Hatanaka, “Astellas”) launched “CNN Tomorrow’s Hero” as a part of its global corporate brand campaign which...
Tokyo, February 13, 2018 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “Astellas”) and Universal Cells, Inc. (CEO: Claudia Mitchell, “Universal Cells”) today...
Tokyo, February 8, 2018 - Astellas Pharma Inc. (President and CEO: Yoshihiko Hatanaka, “Astellas”) announced today that the results of two Phase 3 trials (RAJ3 and RAJ4 trials) on Peficitinib...
Astellas Announces Personnel Changes and Organizational Changes
Read more about Astellas Announces Personnel Changes and Organizational Changes
Pfizer Contacts: For Media Sally Beatty 212-733-6566 sally.beatty@pfizer.com For Investors Ryan Crowe 212-733-8160 ryan.crowe@pfizer.com Astellas Contacts: For Media Tarsis Lopez 847-224-8374...
Tokyo, January 31, 2018 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “Astellas” ) today announced that, at a meeting of the Board of Directors held today, it...
Read more about Astellas Announces Transition to a Company with an Audit & Supervisory Committee
Follow us
